Lead Product(s) : Acetazolamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Merger
Sun Pharma Completes Taro Merger
Details : Sun Pharma will gain access to Taro's pipelines, including Diamox (acetazolamide), an carbonic anhydrase inhibitor used for treating edema due to congestive heart failure in patients.
Brand Name : Diamox
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 24, 2024
Lead Product(s) : Acetazolamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Acetazolamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Merger
Taro Shareholders Approve Merger with Sun Pharma
Details : Sun Pharma will gain access to Taro's pipelines, including Diamox (acetazolamide), an carbonic anhydrase inhibitor used for treating edema due to congestive heart failure in patients.
Brand Name : Diamox
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 23, 2024
Lead Product(s) : Acetazolamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Acetazolamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Merger
Taro Announces Merger Agreement with Sun Pharma
Details : Through the merger, Sun Pharma will gain access to Taro's pipelines, including Diamox (acetazolamide), a carbonic anhydrase inhibitor for treating edema due to congestive heart failure.
Brand Name : Diamox
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 17, 2024
Lead Product(s) : Acetazolamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Intellipharmaceutics Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory (PDD) of Heal...
Brand Name : Desvenlafaxine-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 16, 2022
Lead Product(s) : Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Intellipharmaceutics Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Benzoyl Peroxide
Therapeutic Area : Dermatology
Study Phase : Approved
Recipient : Galderma
Deal Size : $99.3 million
Deal Type : Acquisition
Sun Pharma's US subsidiary acquires Galderma's companies in US, Japan & Canada
Details : Taro Pharmaceutical Industries, has agreed to acquire all of the outstanding capital stock of Galderma ; Proactiv YK ; The Proactiv Company ; used in the business of developing, manufacturing, marketing, selling and distributing products sold under the P...
Brand Name : Proactiv
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 09, 2022
Lead Product(s) : Benzoyl Peroxide
Therapeutic Area : Dermatology
Highest Development Status : Approved
Recipient : Galderma
Deal Size : $99.3 million
Deal Type : Acquisition
Lead Product(s) : Benzoyl Peroxide
Therapeutic Area : Dermatology
Study Phase : Approved
Recipient : Alchemee
Deal Size : Undisclosed
Deal Type : Acquisition
Taro Completes Acquisition of Alchemee
Details : The acquisition includes Alchemee’s business and assets worldwide, including the Proactiv® brand. Alchemee's flagship brand, Proactiv, is America’s 1 acne routine and has been used and trusted by millions around the world for more than 25 years.
Brand Name : Proactiv
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 28, 2022
Lead Product(s) : Benzoyl Peroxide
Therapeutic Area : Dermatology
Highest Development Status : Approved
Recipient : Alchemee
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Deferiprone
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Taro Pharmaceutical Launches Generic Deferiprone in U.S
Details : Deferiprone is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is the generic version of Ferriprox®.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2020
Lead Product(s) : Deferiprone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Crescita Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis® U.S. Licensing Agreement
Details : The Company continues to pursue out-licensing partnerships with focus on approximately 20 countries where Pliaglis has already received regulatory approval.
Brand Name : Pliaglis
Molecule Type : Small molecule
Upfront Cash : $3.9 million
July 28, 2020
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Crescita Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Levofloxacin,Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : NTC
Deal Size : Undisclosed
Deal Type : Licensing Agreement
NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries
Details : NTC Srl has granted exclusive license and distribution rights to one of its R&D products to Taro Pharmaceutical. The product combines a quinolone antibiotic with an anti-inflammatory steroid in eye drops intended to provide an appropriate treatment for p...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 17, 2020
Lead Product(s) : Levofloxacin,Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : NTC
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
